Natera Inc

NASDAQ:NTRA   3:59:59 PM EDT
68.89
-2.30 (-3.23%)
Products, Regulatory

Natera Announces Prospective Randomized Clinical Trial To Evaluate Palbociclib In Early Stage Breast Cancer Patients Who Test Positive With Signatera

Published: 10/02/2020 13:18 GMT
Natera Inc (NTRA) - Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive With Signatera™.
Natera - Dare Will Be Conducted in U.S. Through Criterium, Inc, Which Plans to Identify About 100 Mrd-positive Patients for Enrollment in Study.
Natera Inc - Signatera Molecular Residual Disease (mrd) Test Will Be Used in Dare Study.